Clinical Trial Update: Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating arsenic trioxide, ascorbic acid, dexamethasone, and thalidomide in chronic myeloproliferative disorders, leukemia, and related myelodys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Myeloproliferative Diseases
• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Ascorbic acid (Vitamin C)
• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Status: COMPLETED